Optigenex Inc
Optigenex Inc. engages in the manufacture and sale of healthy age management and beauty care products. The company offers AC-11, a powdered and bioactive rainforest plant extract that helps the body to repair sun and environmental stress-related damage to DNA, and slow down the process of skin aging. It serves manufacturers, distributors, and retailers worldwide in the dietary supplement, as well… Read more
Optigenex Inc (OPGX) - Net Assets
Latest net assets as of December 2010: $-3.71 Million USD
Based on the latest financial reports, Optigenex Inc (OPGX) has net assets worth $-3.71 Million USD as of December 2010.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.90 Million) and total liabilities ($5.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.71 Million |
| % of Total Assets | -194.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | -265.51% |
| 10-Year Change | N/A |
| Growth Volatility | 124.75 |
Optigenex Inc - Net Assets Trend (2004–2010)
This chart illustrates how Optigenex Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Optigenex Inc (2004–2010)
The table below shows the annual net assets of Optigenex Inc from 2004 to 2010.
| Year | Net Assets | Change |
|---|---|---|
| 2010-12-31 | $-3.71 Million | +2.83% |
| 2009-12-31 | $-3.82 Million | +50.33% |
| 2007-12-31 | $-7.68 Million | -58.40% |
| 2006-12-31 | $-4.85 Million | -316.50% |
| 2005-12-31 | $2.24 Million | -67.01% |
| 2004-12-31 | $6.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Optigenex Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1485849400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2010)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $19.72 Million | % |
| Total Equity | $-3.71 Million | 100.00% |
Optigenex Inc Competitors by Market Cap
The table below lists competitors of Optigenex Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zenovia Digital Exchange Corporation
PINK:ZDEC
|
$3.61 |
|
Livewire Ergogenics
PINK:LVVV
|
$3.62 |
|
New Generation Consumer Group Inc
PINK:NGCG
|
$3.62 |
|
Yippy Inc.
PINK:YIPI
|
$3.65 |
|
Quantum Metal Exchange Inc
PINK:QMEI
|
$2.97 |
|
PMV Consumer Acquisition Corp
PINK:PMVCW
|
$2.97 |
|
Ultrack Systems Inc
PINK:MJLB
|
$2.96 |
|
Zalemark Holding Co
PINK:ZMRK
|
$2.96 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Optigenex Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2009 to 2010, total equity changed from -3,815,578 to -3,707,471, a change of 108,107.
- Net loss of 685,132 reduced equity.
- Other factors increased equity by 793,239.
Equity Change Factors (2009 to 2010)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-685.13K | -18.48% |
| Other Changes | $793.24K | +21.4% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Optigenex Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Optigenex Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -69.12%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-66.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -85.33% | -1708.57% | 0.04x | 1.16x | $-6.47 Million |
| 2005 | -312.32% | -2518.13% | 0.05x | 2.73x | $-7.22 Million |
| 2006 | 0.00% | -2444.96% | 0.11x | 0.00x | $-6.87 Million |
| 2007 | 0.00% | -621.88% | 0.25x | 0.00x | $-2.13 Million |
| 2009 | 0.00% | -102.15% | 0.34x | 0.00x | $-320.80K |
| 2010 | 0.00% | -69.12% | 0.52x | 0.00x | $-314.38K |
Industry Comparison
This section compares Optigenex Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Optigenex Inc (OPGX) | $-3.71 Million | -85.33% | N/A | $2.97 |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |